Stryker Corporation $SYK Shares Sold by Dnca Finance

Dnca Finance decreased its stake in Stryker Corporation (NYSE:SYK) by 23.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,720 shares of the medical technology company’s stock after selling 4,930 shares during the quarter. Dnca Finance’s holdings in Stryker were worth $5,811,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank acquired a new position in Stryker in the second quarter valued at approximately $1,882,173,000. Alliancebernstein L.P. boosted its position in Stryker by 307.6% in the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after purchasing an additional 4,223,366 shares in the last quarter. Corient Private Wealth LLC grew its stake in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after purchasing an additional 1,146,998 shares during the period. Strive Asset Management LLC purchased a new position in shares of Stryker during the 3rd quarter valued at approximately $227,389,000. Finally, ABN AMRO Bank N.V. purchased a new position in Stryker in the second quarter valued at $191,047,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 0.1%

SYK opened at $336.95 on Friday. The business has a fifty day moving average price of $365.20 and a 200 day moving average price of $367.71. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. Stryker Corporation has a 12 month low of $328.23 and a 12 month high of $404.87. The stock has a market capitalization of $128.95 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 1.97 and a beta of 0.85.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $7.17 billion for the quarter, compared to analysts’ expectations of $7.12 billion. During the same quarter last year, the company earned $4.01 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. Sell-side analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio is 41.90%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total value of $90,730,000.00. Following the sale, the director directly owned 2,457,331 shares in the company, valued at $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on SYK. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $435.00 target price on shares of Stryker in a research note on Friday, November 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Truist Financial lowered their price target on shares of Stryker from $400.00 to $392.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. Jefferies Financial Group reiterated a “buy” rating and issued a $465.00 price objective on shares of Stryker in a report on Wednesday, March 4th. Finally, Barclays reaffirmed an “overweight” rating and set a $469.00 target price on shares of Stryker in a research note on Monday, February 2nd. Fourteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $428.61.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Citi and some analysts view the pullback as a potential buying opportunity given Stryker’s fundamentals and upcoming catalysts — Citi put together a “90‑day catalyst watch” that sees upside despite the outage. Citi Sees Upside
• Positive Sentiment: Technicals may offer support: commentators note shares became oversold after the sell‑off and found support at a prior level, suggesting a possible technical bounce for traders. Stock Of The Day: Where Is The Bottom For Stryker?
• Neutral Sentiment: Stryker has publicly confirmed a cybersecurity incident and is investigating; the company is communicating updates as the situation evolves. Company Announcement
• Neutral Sentiment: Reporting shows the attack is causing real operational disruption to order processing, manufacturing and shipments — facts investors must watch to judge duration and revenue impact. Reuters: Disruption Report
• Negative Sentiment: Hackers claiming Iran linkage (group “Handala”) say the attack included destructive “wiper” activity and exfiltration of large volumes of data — allegations that raise the risk of extended downtime and regulatory/PR fallout. IBTimes: Hacker Claim
• Negative Sentiment: Operational paralysis from the incident has already pressured the stock, with multiple outlets reporting multi‑percent intraday declines as orders and shipments stall. Yahoo: Shares Fall
• Negative Sentiment: Social‑media driven selling amplified volatility — a viral Reddit thread and related headlines accelerated the recent drop, adding short‑term downside risk beyond fundamentals. 24/7 Wall St.: Reddit Impact

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.